Dementia Drugs Market, By Drug Class (Monoamine Oxidase Inhibitors (MAOI), Cholinesterase Inhibitors, Glutamate Inhibitors and Others), By Distribution Channel (Online Channel and Offline Channel) – Global Industry Insights, Trends and Forecast, 2017-2025

Created On: Jul-2018
Report ID: IR55
Format: PDF

Dementia Drugs Market Size: Introduction

Dementia is a type of a disease that affects the functionality of a human brain and reduces the thinking ability. The collection of protein (beta amyloid), in the spaces between the nerve cells due to the genetic mutation is the key factor that results to dementia. Alzheimer’s, the most common and largest form of dementia disease, which is perceived in the people aged 65 years and above.  Although there is no cure or treatment for dementia disease that stop or slows its process, but drug treatment is being provided that may temporarily improve the symptom.

Market Dynamics

The Dementia Drugs Market Size is expected to witness substantial growth owing to the rise in number of drugs in the pipeline, which further indicates the fulfillment of medication requirement of patients suffering from dementia symptoms and prevalent disease such as Alzheimer’s. For instance, in 2017, according to Translational Research and Clinical Intervention have noted the 105 new drugs in the pipeline, among which 25 are in phase 1, 52 are in phase 2 and 28 are present in phase 3.  

The growth in the Alzheimer’s disease across the globe is escalating the demand of dementia drugs. In 2016 according to World Alzheimer Report, 46.5 million people have been recorded that are suffering from Alzheimer and is further expected to rise by 20% in the coming years. In addition, increasing number of geriatric population has escalated the growth of Alzheimer’s disease which further increases the opportunity of dementia drugs market. For instance, in 2017 according to World Population Prospects (WPP), people diagnosed with Alzheimer’s is being recorded as 962 million, and is expected to rise by 13% over the coming years. However, stringent regulations on the commercialization of dementia drugs, coupled with inefficacy and failure of drugs in clinical trials can hamper the growth of the dementia drug market. Side-effects associated with the consumption of dementia drugs such as muscle spasms, hypertension, nausea, and others can negatively affect the growth of the dementia drugs market share.

Segment Analysis:

Monoamine Oxidase Inhibitors segment is anticipated to be the fastest growing drug class during the forecast period, due to their less toxic nature and high efficacy in aiding patients with extended life span. The availability of MAOIs like Emsam, which is a transdermal patch and applied on skin is less likely to cause dietary complications as compared to the drugs that are consumed through oral administration.

On the basis of distribution channel, the in dementia drugs market size is categorized as offline channel, and online channel. The offline stores includes retail and hospital pharmacies are expected to hold the major revenue share market during the forecast period, owing to the increased regulations of major drug evaluation regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others, on sale of dementia drugs and increased focus on sale and purchase of dementia drugs on the prescription provided by an authorized medical professional.

Regional Insight:

Asia-Pacific is expected to dominate the dementia drugs market size during the forecast year owing the rising number of geriatric population in this region primarily in China, Japan and India. For instance, in 2015, according to Alzheimer’s Disease International Association, 9.8 million people are diagnosed with dementia in East Asia followed by Western Europe accounts for 7.4 million. In 2015, Japan’s Ministry of Health, Labour and Welfare Association, announced the launch of ‘New Orange Plan’, which aimed at early detection of dementia symptoms, increased medical facilities for patients suffering from the disease, and development of novel drugs.

 

North America is expected to grow with a highest CAGR over the coming years owing to the increasing clinical study on developing drugs for dementia treatment, coupled with favorable reimbursement policies. For instance, in 2018, according to NCBI, there are around 112 agents in the current Alzheimer’s disease treatment pipeline.  Presence of key players in dementia drugs market like Merck & Co., Eli Lilly and Company, Biogen Inc., and others, will further be responsible for generating high revenue shares from the region.

Competitive Landscape:

The key players operating in dementia drugs market are Janssen Pharmaceuticals, Inc., Eisai, Inc., Forest Laboratories, Inc., Biogen Pharmaceuticals, Sanofi S.A., F. Hoffmann-La Roche, Merck & Co., Inc.., Eli Lilly and Company, Valeant Pharmaceutical International, Pfizer Inc., AstraZeneca GmbH, Novartis AG, and Teva Pharmaceuticals Industries Ltd.  To stay competitive in the market, the players are engaged in strategic acquisition, collaboration and new product enhancement. For instance, in 2016, Teva Pharmaceutical Industries Limited acquired the company named Actavis Generics, in 2016 in order to improve their generic and specialty medicines product portfolio.

Our Research Approach Includes
  •  Market Outlining
  •  Framing discussion guide
  •  Data Validation
  • Data Analysis
  •  Re-Validation and Finalization of Data
  •  Report Insights and Publishing
Our Research Approach Includes
  •  Market Outlining
  •  Framing discussion guide
  •  Data Validation
  • Data Analysis
  •  Re-Validation and Finalization of Data
  •  Report Insights and Publishing
Reach Out to us